GlassScriptPhysician profile
Andrew Joseph
NPI 1639756703
$833.10
in general payments reported to CMS, 2019-2025
20 companies · $507 in 2025
The $507 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $326 · 2025: $507.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $833.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $833.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $225.99 | 2024-2025 | Airsupra, Farxiga |
| Abbvie INC. | $74.90 | 2024-2025 | |
| Exact Sciences Corporation | $71.88 | 2025 | Cologuard Collection Kit |
| Amgen INC. | $67.41 | 2024-2025 | Repatha, Otezla, Otezla |
| Astellas Pharma US INC | $47.43 | 2024-2025 | Veozah |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $35.41 | 2025 | Caplyta |
| Abbott Laboratories | $33.11 | 2025 | Freestyle Libre 3 |
| Lilly USA, LLC | $32.37 | 2024-2025 | Mounjaro, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.07 | 2025 | Xifaxan |
| Mylan Specialty L.P. | $28.06 | 2024 | Yupelri |
| Nevro Corp. | $22.35 | 2024 | Senza |
| Xeris Pharmaceuticals, INC. | $22.10 | 2025 | Gvoke Hypopen |
| Bayer Healthcare Pharmaceuticals INC. | $21.59 | 2025 | |
| Viatris Specialty LLC | $19.71 | 2025 | Yupelri |
| Merck Sharp & Dohme LLC | $19.55 | 2024 | Gardasil 9, Capvaxive, Gardasil |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $16.86 | 2025 | |
| Smith+Nephew, INC. | $16.46 | 2025 | Collagenase Santyl |
| Pfizer INC. | $16.11 | 2025 | |
| Sumitomo Pharma America, INC. | $15.31 | 2025 | Gemtesa |
| Aimmune Therapeutics, INC. | $14.43 | 2025 | Zenpep |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Joseph listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.